The purpose of this legislation is to address unfair international trade practices by high-income countries that exploit U.S. pharmaceutical innovations. It aims to ensure that these countries do not undermine the value of American-developed medicines through non-market-based pricing and policies. The legislation seeks to protect U.S. pharmaceutical manufacturers and consumers by promoting fair competition and access to innovative treatments. Key provisions of the legislation include the establishment of a Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative's office.